SCHEMBL14988808

SCHEMBL14988808

Cc1ccc(C)c(-c2ccc(N=Nc3cc(S(=O)(=O)O)c4ccccc4c3N)cn2)c1.[NaH]

nearest known ligand 0.80

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SENP2 Q9HC62 3/20 0.62
▸ SENP1 Q9P0U3 3/20 0.62
▸ SUMO2 P61956 2/20 0.62
▸ SUMO1 P63165 2/20 0.62
▸ SENP7 Q9BQF6 2/20 0.62
▸ SENP3 Q9H4L4 2/20 0.61
▸ MEN1 O00255 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ APP P05067 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ THRB P10828 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ ALOX12 P18054 1/20 0.56
▸ SNCA P37840 1/20 0.56
▸ RECQL P46063 1/20 0.56
▸ BLM P54132 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14988806 1.00 SENP2 (0.62) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL18044324 0.99 SENP2 (0.63) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL15120173 0.99 SENP2 (0.63) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL29697088 0.99 SENP2 (0.63) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL17319311 0.91 SENP2 (0.69) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL14988621 0.91 SENP2 (0.66) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL14988626 0.91 SENP2 (0.66) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL14988152 0.91 SENP2 (0.57) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL14988766 0.91 SENP2 (0.60) SENP2SENP1SUMO2SUMO1SENP7
SCHEMBL14988149 0.91 SENP2 (0.57) SENP2SENP1SUMO2SUMO1SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206129-B2 Agent for treatment of eye diseases DAITO CHEMIX CORPORATION (JP) 2015-12-08 — — US claimed
EP-3042658-B1 MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE UNIV KYOTO (JP) 2019-01-16 — — EP disclosed
EP-2959903-B1 MEDICINE FOR TREATING EYE DISEASE UNIV KYOTO (JP) 2018-10-03 — — EP disclosed
US-9931351-B2 Method for improving leptin resistance KYOTO UNIVERSITY (JP) 2018-04-03 — — US disclosed
US-9782420-B2 Method for treating eye diseases KYOTO UNIVERSITY (JP) 2017-10-10 — — US disclosed
US-9573887-B2 Naphthalene derivative DAITO CHEMIX CORPORATION (JP) 2017-02-21 — — US disclosed
US-20160303144-A1 Medicinal Composition Improving Leptin Resistance KYOTO UNIVERSITY (JP) 2016-10-20 — — US disclosed
EP-2599771-B1 NAPHTHALENE DERIVATIVE DAITO CHEMIX CORP (JP) 2016-09-14 — — EP disclosed
EP-3042658-A1 MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE Kyoto University (JP) 2016-07-13 — — EP disclosed
US-20160000810-A1 Method For Treating Eye Diseases KYOTO UNIVERSITY (JP) 2016-01-07 — — US disclosed
EP-2959903-A1 MEDICINE FOR TREATING EYE DISEASE Kyoto University (JP) 2015-12-30 — — EP disclosed
US-9206129-B2 Agent for treatment of eye diseases DAITO CHEMIX CORPORATION (JP) 2015-12-08 — — US disclosed
EP-2623494-B1 AGENT FOR TREATMENT OF EYE DISEASES DAITO CHEMIX CORP (JP) 2015-09-02 — — EP disclosed
US-20140148416-A1 Agent for Treatment of Eye Diseases KYOTO UNIVERSITY (JP) 2014-05-29 — — US disclosed
EP-2623494-A1 AGENT FOR TREATMENT OF EYE DISEASES Daito Chemix Corporation (JP) 2013-08-07 — — EP disclosed
US-20130184241-A1 Naphthalene Derivative KYOTO UNIVERSITY (JP) 2013-07-18 — — US disclosed
EP-2599771-A1 NAPHTHALENE DERIVATIVE Daito Chemix Corporation (JP) 2013-06-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000810-A1 Method For Treating Eye Diseases CFB, AGER, CFH SENP2 3567/4885SENP1 3495/4885SUMO2 3428/4885
US-20140148416-A1 Agent for Treatment of Eye Diseases PDE6A, ALDH1A2, PDE6D SENP2 3080/4885SENP1 3643/4885SUMO2 3028/4885
US-20160303144-A1 Medicinal Composition Improving Leptin Resistance LIPC, ADIPOR1, GPR119 SENP2 3218/4885SENP1 3152/4885SUMO2 4540/4885
US-20130184241-A1 Naphthalene Derivative VCP, NOC2L, VAT1 SENP2 754/4885SENP1 615/4885SUMO2 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback